Results 31 to 40 of about 5,148 (157)

Virtual Cocrystal Screening of Adefovir Dipivoxyl: Identification of New Solid Forms with Improved Dissolution and Permeation Profiles

Pharmaceutics, 2022
The application of a computational screening methodology based on the calculation of intermolecular interaction energies has guided the discovery of new multicomponent solid forms of the oral antiviral Adefovir Dipivoxyl.
Rafael Barbas, Hanan Fael, Samuel Lee, Rebeca Ruiz, Christopher A. Hunter, Elisabet Fuguet, Clara Ràfols, Rafel Prohens   +7 more
doaj   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report

Journal of Medical Case Reports, 2019
Background Adefovir dipivoxil is a nucleotide analogue that is approved for treatment of chronic hepatitis B. Adefovir dipivoxil is associated with proximal tubular dysfunction, resulting in Fanconi syndrome, which can cause secondary hypophosphatemic ...
Tomohisa Kunii, Toshie Iijima, Teruo Jojima, Masanori Shimizu, Masato Kase, Shintaro Sakurai, Takahiko Kogai, Isao Usui, Yoshimasa Aso   +8 more
doaj   +1 more source

Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery

Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.
A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju, Abimbola Motunrayo Folami, Saheed Sabiu, Feroz Mahomed Swalaha   +3 more
wiley   +1 more source

Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions

Cell Proliferation, Volume 59, Issue 7, July 2026.
This review outlines kidney organoid differentiation strategies, key developmental mechanisms, and engineering and multi‐omics approaches driving their progress toward regenerative medicine. ABSTRACT Chronic kidney disease (CKD) has emerged as a critical public health challenge worldwide, and organ donor shortages underscore the urgent need for ...
Bohong Guo, Jingyuan Zhang, Xuening Fang, Yangyang Liu, Yueyang Deng, Yuxin Xue, Zhengxi Wang, Xiaotao Dong, Mengqi Jia, Xiaodong Li   +9 more
wiley   +1 more source

Liver Transplantation for HBV‐Related Disease in France: NUC Type Before LT Is Associated With Patient Survival

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background & Aims Liver transplantation (LT) is indicated for liver complications related to hepatitis B virus (HBV) infection: acute liver failure (ALF), decompensated cirrhosis or hepatocellular carcinoma (HCC). The present study aimed to describe and evaluate patient survival after LT for HBV‐related disease in France and identify the ...
Isaure Bienvenue, Olivier Roux, Audrey Coilly, Armand Abergel, Teresa Antonini, Thierry Artzner, Olivier Boillot, Faiza Chermak, Filomena Conti, Sébastien Dharancy, Christophe Duvoux, Laure Elkrief, Marwin Farrugia, Claire Francoz, Baptiste Giguet, Jean Hardwigsen, Pauline Houssel‐Debry, Marie‐Noëlle Hilleret, Nassim Kamar, Marianne Latournerie, Magdalena Meszaros, Sylvie Radenne, Bruno Roche, Ephrem Salamé, Delphine Verhoeven‐Weil, Didier Samuel, Fabien Zoulim, Jérôme Dumortier, François Villeret   +28 more
wiley   +1 more source

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis

Virology Journal, 2011
Background Although entacavir and adefovir were widely used in most Asian countries, there were few conclusions drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian patients with chronic ...
Zhao Jun, Liu Weiwei, Zhao Pan, Guan Qun
doaj   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, Volume 10, Issue 2, Page 205-241, June 2026.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

Adefovir Dipivoxil

Acta Médica Costarricense, 2008
El adefovir es un nucleótido que se utiliza por vía oral, sin resistencia conocida hasta los dos años de tratamiento. Actúa en los pacientes con hepatitis B crónica Age+ y Age-, es efectivo en resistentes a lamivudina.
Francisco Javier Hevia-Urrutia
doaj  

A Low Viral Load Predicts a Higher Initial Virologic Response to Adefovir in Patients with Lamivudine-Resistant Chronic Hepatitis B

Gut and Liver, 2010
Background/Aims: Adefovir (ADV) is the preferred drug for treating lamivudine (LAM)-resistant hepatitis B. However, not all patients who face virologic breakthrough during LAM treatment respond to ADV.
doaj   +1 more source